Global Cancer Screening Market

Cancer Screening Comprehensive Study by Type (Mammography Screening, Magnetic Resonance Imaging (MRI) Screening, Ultrasound Screening), Application (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes), Diseases (Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Liver-Lung Cancer, Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer) Players and Region - Global Market Outlook to 2028

Cancer Screening Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Cancer Screening is a device that used to detect the cancer before symptom appears. It is beneficial in find out the cancer prevention, early stage detection and subsequent treatment and others. Cancer Screening market has high growth prospects due to various risk factor such as unhealthy lifestyle, obesity and hormone replacement therapy. According to National Cancer Institute in 2018,1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will died from the disease. Further, increasing demand for next-generation sequencing and breath biopsy/volatile organic compound expected to drive the market over the forecasted period.

AttributesDetails
Study Period2018-2028
Base Year2022
High Growth MarketAsia Pacific
UnitValue (USD Million)
Key Companies ProfiledAbbott (United States), Roche (Switzerland), Fujirebio Diagnostics, Inc. (United States), BioMérieux (France), Beckman Coulter (United States), Clarient (Switzerland), Siemens (Germany), DiaSorin (Italy) and Qiagen (Germany)


This growth is primarily driven by Increase Incidence of Cancer Diseases. and Rising Number of Diagnostic and Research Centers across Developing Countries.

Globally, a noticeable market trend is evident Collaboration and Tie Up Of Leading Players The Medical Devices sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Abbott (United States), Roche (Switzerland), Fujirebio Diagnostics, Inc. (United States), BioMérieux (France), Beckman Coulter (United States), Clarient (Switzerland), Siemens (Germany), DiaSorin (Italy) and Qiagen (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. Cancer Screening market companies operating in these industries are focusing more on efficient growth, improvement of operational efficiency and productivity, achieving high safety standards, and focusing on maintaining sustainable development. The market is highly competitive with a few players occupying the major share. The key players are highly focused on developing and innovating new strategies to maintain their market position and customer base. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launches, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Key Developments in the Market:
In June 2019, Biodesix, Inc. acquired Oncimmune laboratories and incidental pulmonary nodule (IPN) malignancy test in the United States. This acquisition is beneficial in providing blood-based diagnostic solutions for lung cancer that provide actionable results and reimbursement with best-in-class turnaround time.
In October 2018, Telerad Tech launched an Artifical Intelligence screening equipment for detecting early stage of breast cancer. It also offers different processes of imaging data to recognize radiologic features and mammogram.

Influencing Trend:
Collaboration and Tie Up Of Leading Players

Market Growth Drivers:
Increase Incidence of Cancer Diseases. and Rising Number of Diagnostic and Research Centers across Developing Countries

Challenges:
Fluctuation of Data and Accuracy of the Equipment is anticipated to challenge the market

Restraints:
High Cost associated within Cancer Screening. and Risk Associated with Exposure of Radiation Hamper the Market

Opportunities:
Technological Advancements such as Liquid Biopsy Technique Boost the Cancer Screening Market and Raising Awareness among the Customer.

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Cancer Screening Market
- Analysis about New Entrants in Cancer Screening Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Cancer Screening Study Sheds Light on
— The Cancer Screening Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cancer Screening industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cancer Screening industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Mammography Screening
  • Magnetic Resonance Imaging (MRI) Screening
  • Ultrasound Screening
By Application
  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
By Diseases
  • Bladder Cancer
  • Breast Cancer
  • Colon and Rectal Cancer
  • Endometrial Cancer
  • Kidney Cancer
  • Leukemia
  • Liver-Lung Cancer
  • Melanoma
  • Non-Hodgkin Lymphoma
  • Pancreatic Cancer
  • Prostate Cancer
  • Thyroid Cancer

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase Incidence of Cancer Diseases.
      • 3.2.2. Rising Number of Diagnostic and Research Centers across Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. Fluctuation of Data and Accuracy of the Equipment is anticipated to challenge the market
    • 3.4. Market Trends
      • 3.4.1. Collaboration and Tie Up Of Leading Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Screening, by Type, Application, Diseases and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Screening (Value)
      • 5.2.1. Global Cancer Screening by: Type (Value)
        • 5.2.1.1. Mammography Screening
        • 5.2.1.2. Magnetic Resonance Imaging (MRI) Screening
        • 5.2.1.3. Ultrasound Screening
      • 5.2.2. Global Cancer Screening by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostic Laboratories
        • 5.2.2.3. Diagnostic Imaging Centers
        • 5.2.2.4. Cancer Research Institutes
      • 5.2.3. Global Cancer Screening by: Diseases (Value)
        • 5.2.3.1. Bladder Cancer
        • 5.2.3.2. Breast Cancer
        • 5.2.3.3. Colon and Rectal Cancer
        • 5.2.3.4. Endometrial Cancer
        • 5.2.3.5. Kidney Cancer
        • 5.2.3.6. Leukemia
        • 5.2.3.7. Liver-Lung Cancer
        • 5.2.3.8. Melanoma
        • 5.2.3.9. Non-Hodgkin Lymphoma
        • 5.2.3.10. Pancreatic Cancer
        • 5.2.3.11. Prostate Cancer
        • 5.2.3.12. Thyroid Cancer
      • 5.2.4. Global Cancer Screening Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cancer Screening (Price)
      • 5.3.1. Global Cancer Screening by: Type (Price)
  • 6. Cancer Screening: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Fujirebio Diagnostics, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BioMérieux (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Beckman Coulter (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Clarient (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. DiaSorin (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Qiagen (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Cancer Screening Sale, by Type, Application, Diseases and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Screening (Value)
      • 7.2.1. Global Cancer Screening by: Type (Value)
        • 7.2.1.1. Mammography Screening
        • 7.2.1.2. Magnetic Resonance Imaging (MRI) Screening
        • 7.2.1.3. Ultrasound Screening
      • 7.2.2. Global Cancer Screening by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostic Laboratories
        • 7.2.2.3. Diagnostic Imaging Centers
        • 7.2.2.4. Cancer Research Institutes
      • 7.2.3. Global Cancer Screening by: Diseases (Value)
        • 7.2.3.1. Bladder Cancer
        • 7.2.3.2. Breast Cancer
        • 7.2.3.3. Colon and Rectal Cancer
        • 7.2.3.4. Endometrial Cancer
        • 7.2.3.5. Kidney Cancer
        • 7.2.3.6. Leukemia
        • 7.2.3.7. Liver-Lung Cancer
        • 7.2.3.8. Melanoma
        • 7.2.3.9. Non-Hodgkin Lymphoma
        • 7.2.3.10. Pancreatic Cancer
        • 7.2.3.11. Prostate Cancer
        • 7.2.3.12. Thyroid Cancer
      • 7.2.4. Global Cancer Screening Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cancer Screening (Price)
      • 7.3.1. Global Cancer Screening by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Screening: by Type(USD Million)
  • Table 2. Cancer Screening Mammography Screening , by Region USD Million (2017-2022)
  • Table 3. Cancer Screening Magnetic Resonance Imaging (MRI) Screening , by Region USD Million (2017-2022)
  • Table 4. Cancer Screening Ultrasound Screening , by Region USD Million (2017-2022)
  • Table 5. Cancer Screening: by Application(USD Million)
  • Table 6. Cancer Screening Hospitals , by Region USD Million (2017-2022)
  • Table 7. Cancer Screening Diagnostic Laboratories , by Region USD Million (2017-2022)
  • Table 8. Cancer Screening Diagnostic Imaging Centers , by Region USD Million (2017-2022)
  • Table 9. Cancer Screening Cancer Research Institutes , by Region USD Million (2017-2022)
  • Table 10. Cancer Screening: by Diseases(USD Million)
  • Table 11. Cancer Screening Bladder Cancer , by Region USD Million (2017-2022)
  • Table 12. Cancer Screening Breast Cancer , by Region USD Million (2017-2022)
  • Table 13. Cancer Screening Colon and Rectal Cancer , by Region USD Million (2017-2022)
  • Table 14. Cancer Screening Endometrial Cancer , by Region USD Million (2017-2022)
  • Table 15. Cancer Screening Kidney Cancer , by Region USD Million (2017-2022)
  • Table 16. Cancer Screening Leukemia , by Region USD Million (2017-2022)
  • Table 17. Cancer Screening Liver-Lung Cancer , by Region USD Million (2017-2022)
  • Table 18. Cancer Screening Melanoma , by Region USD Million (2017-2022)
  • Table 19. Cancer Screening Non-Hodgkin Lymphoma , by Region USD Million (2017-2022)
  • Table 20. Cancer Screening Pancreatic Cancer , by Region USD Million (2017-2022)
  • Table 21. Cancer Screening Prostate Cancer , by Region USD Million (2017-2022)
  • Table 22. Cancer Screening Thyroid Cancer , by Region USD Million (2017-2022)
  • Table 23. South America Cancer Screening, by Country USD Million (2017-2022)
  • Table 24. South America Cancer Screening, by Type USD Million (2017-2022)
  • Table 25. South America Cancer Screening, by Application USD Million (2017-2022)
  • Table 26. South America Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 27. Brazil Cancer Screening, by Type USD Million (2017-2022)
  • Table 28. Brazil Cancer Screening, by Application USD Million (2017-2022)
  • Table 29. Brazil Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 30. Argentina Cancer Screening, by Type USD Million (2017-2022)
  • Table 31. Argentina Cancer Screening, by Application USD Million (2017-2022)
  • Table 32. Argentina Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 33. Rest of South America Cancer Screening, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Cancer Screening, by Application USD Million (2017-2022)
  • Table 35. Rest of South America Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 36. Asia Pacific Cancer Screening, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Cancer Screening, by Type USD Million (2017-2022)
  • Table 38. Asia Pacific Cancer Screening, by Application USD Million (2017-2022)
  • Table 39. Asia Pacific Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 40. China Cancer Screening, by Type USD Million (2017-2022)
  • Table 41. China Cancer Screening, by Application USD Million (2017-2022)
  • Table 42. China Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 43. Japan Cancer Screening, by Type USD Million (2017-2022)
  • Table 44. Japan Cancer Screening, by Application USD Million (2017-2022)
  • Table 45. Japan Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 46. India Cancer Screening, by Type USD Million (2017-2022)
  • Table 47. India Cancer Screening, by Application USD Million (2017-2022)
  • Table 48. India Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 49. South Korea Cancer Screening, by Type USD Million (2017-2022)
  • Table 50. South Korea Cancer Screening, by Application USD Million (2017-2022)
  • Table 51. South Korea Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 52. Taiwan Cancer Screening, by Type USD Million (2017-2022)
  • Table 53. Taiwan Cancer Screening, by Application USD Million (2017-2022)
  • Table 54. Taiwan Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 55. Australia Cancer Screening, by Type USD Million (2017-2022)
  • Table 56. Australia Cancer Screening, by Application USD Million (2017-2022)
  • Table 57. Australia Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 58. Rest of Asia-Pacific Cancer Screening, by Type USD Million (2017-2022)
  • Table 59. Rest of Asia-Pacific Cancer Screening, by Application USD Million (2017-2022)
  • Table 60. Rest of Asia-Pacific Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 61. Europe Cancer Screening, by Country USD Million (2017-2022)
  • Table 62. Europe Cancer Screening, by Type USD Million (2017-2022)
  • Table 63. Europe Cancer Screening, by Application USD Million (2017-2022)
  • Table 64. Europe Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 65. Germany Cancer Screening, by Type USD Million (2017-2022)
  • Table 66. Germany Cancer Screening, by Application USD Million (2017-2022)
  • Table 67. Germany Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 68. France Cancer Screening, by Type USD Million (2017-2022)
  • Table 69. France Cancer Screening, by Application USD Million (2017-2022)
  • Table 70. France Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 71. Italy Cancer Screening, by Type USD Million (2017-2022)
  • Table 72. Italy Cancer Screening, by Application USD Million (2017-2022)
  • Table 73. Italy Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 74. United Kingdom Cancer Screening, by Type USD Million (2017-2022)
  • Table 75. United Kingdom Cancer Screening, by Application USD Million (2017-2022)
  • Table 76. United Kingdom Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 77. Netherlands Cancer Screening, by Type USD Million (2017-2022)
  • Table 78. Netherlands Cancer Screening, by Application USD Million (2017-2022)
  • Table 79. Netherlands Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 80. Rest of Europe Cancer Screening, by Type USD Million (2017-2022)
  • Table 81. Rest of Europe Cancer Screening, by Application USD Million (2017-2022)
  • Table 82. Rest of Europe Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 83. MEA Cancer Screening, by Country USD Million (2017-2022)
  • Table 84. MEA Cancer Screening, by Type USD Million (2017-2022)
  • Table 85. MEA Cancer Screening, by Application USD Million (2017-2022)
  • Table 86. MEA Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 87. Middle East Cancer Screening, by Type USD Million (2017-2022)
  • Table 88. Middle East Cancer Screening, by Application USD Million (2017-2022)
  • Table 89. Middle East Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 90. Africa Cancer Screening, by Type USD Million (2017-2022)
  • Table 91. Africa Cancer Screening, by Application USD Million (2017-2022)
  • Table 92. Africa Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 93. North America Cancer Screening, by Country USD Million (2017-2022)
  • Table 94. North America Cancer Screening, by Type USD Million (2017-2022)
  • Table 95. North America Cancer Screening, by Application USD Million (2017-2022)
  • Table 96. North America Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 97. United States Cancer Screening, by Type USD Million (2017-2022)
  • Table 98. United States Cancer Screening, by Application USD Million (2017-2022)
  • Table 99. United States Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 100. Canada Cancer Screening, by Type USD Million (2017-2022)
  • Table 101. Canada Cancer Screening, by Application USD Million (2017-2022)
  • Table 102. Canada Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 103. Mexico Cancer Screening, by Type USD Million (2017-2022)
  • Table 104. Mexico Cancer Screening, by Application USD Million (2017-2022)
  • Table 105. Mexico Cancer Screening, by Diseases USD Million (2017-2022)
  • Table 106. Cancer Screening: by Type(USD/Units)
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Cancer Screening: by Type(USD Million)
  • Table 117. Cancer Screening Mammography Screening , by Region USD Million (2023-2028)
  • Table 118. Cancer Screening Magnetic Resonance Imaging (MRI) Screening , by Region USD Million (2023-2028)
  • Table 119. Cancer Screening Ultrasound Screening , by Region USD Million (2023-2028)
  • Table 120. Cancer Screening: by Application(USD Million)
  • Table 121. Cancer Screening Hospitals , by Region USD Million (2023-2028)
  • Table 122. Cancer Screening Diagnostic Laboratories , by Region USD Million (2023-2028)
  • Table 123. Cancer Screening Diagnostic Imaging Centers , by Region USD Million (2023-2028)
  • Table 124. Cancer Screening Cancer Research Institutes , by Region USD Million (2023-2028)
  • Table 125. Cancer Screening: by Diseases(USD Million)
  • Table 126. Cancer Screening Bladder Cancer , by Region USD Million (2023-2028)
  • Table 127. Cancer Screening Breast Cancer , by Region USD Million (2023-2028)
  • Table 128. Cancer Screening Colon and Rectal Cancer , by Region USD Million (2023-2028)
  • Table 129. Cancer Screening Endometrial Cancer , by Region USD Million (2023-2028)
  • Table 130. Cancer Screening Kidney Cancer , by Region USD Million (2023-2028)
  • Table 131. Cancer Screening Leukemia , by Region USD Million (2023-2028)
  • Table 132. Cancer Screening Liver-Lung Cancer , by Region USD Million (2023-2028)
  • Table 133. Cancer Screening Melanoma , by Region USD Million (2023-2028)
  • Table 134. Cancer Screening Non-Hodgkin Lymphoma , by Region USD Million (2023-2028)
  • Table 135. Cancer Screening Pancreatic Cancer , by Region USD Million (2023-2028)
  • Table 136. Cancer Screening Prostate Cancer , by Region USD Million (2023-2028)
  • Table 137. Cancer Screening Thyroid Cancer , by Region USD Million (2023-2028)
  • Table 138. South America Cancer Screening, by Country USD Million (2023-2028)
  • Table 139. South America Cancer Screening, by Type USD Million (2023-2028)
  • Table 140. South America Cancer Screening, by Application USD Million (2023-2028)
  • Table 141. South America Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 142. Brazil Cancer Screening, by Type USD Million (2023-2028)
  • Table 143. Brazil Cancer Screening, by Application USD Million (2023-2028)
  • Table 144. Brazil Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 145. Argentina Cancer Screening, by Type USD Million (2023-2028)
  • Table 146. Argentina Cancer Screening, by Application USD Million (2023-2028)
  • Table 147. Argentina Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 148. Rest of South America Cancer Screening, by Type USD Million (2023-2028)
  • Table 149. Rest of South America Cancer Screening, by Application USD Million (2023-2028)
  • Table 150. Rest of South America Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 151. Asia Pacific Cancer Screening, by Country USD Million (2023-2028)
  • Table 152. Asia Pacific Cancer Screening, by Type USD Million (2023-2028)
  • Table 153. Asia Pacific Cancer Screening, by Application USD Million (2023-2028)
  • Table 154. Asia Pacific Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 155. China Cancer Screening, by Type USD Million (2023-2028)
  • Table 156. China Cancer Screening, by Application USD Million (2023-2028)
  • Table 157. China Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 158. Japan Cancer Screening, by Type USD Million (2023-2028)
  • Table 159. Japan Cancer Screening, by Application USD Million (2023-2028)
  • Table 160. Japan Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 161. India Cancer Screening, by Type USD Million (2023-2028)
  • Table 162. India Cancer Screening, by Application USD Million (2023-2028)
  • Table 163. India Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 164. South Korea Cancer Screening, by Type USD Million (2023-2028)
  • Table 165. South Korea Cancer Screening, by Application USD Million (2023-2028)
  • Table 166. South Korea Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 167. Taiwan Cancer Screening, by Type USD Million (2023-2028)
  • Table 168. Taiwan Cancer Screening, by Application USD Million (2023-2028)
  • Table 169. Taiwan Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 170. Australia Cancer Screening, by Type USD Million (2023-2028)
  • Table 171. Australia Cancer Screening, by Application USD Million (2023-2028)
  • Table 172. Australia Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 173. Rest of Asia-Pacific Cancer Screening, by Type USD Million (2023-2028)
  • Table 174. Rest of Asia-Pacific Cancer Screening, by Application USD Million (2023-2028)
  • Table 175. Rest of Asia-Pacific Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 176. Europe Cancer Screening, by Country USD Million (2023-2028)
  • Table 177. Europe Cancer Screening, by Type USD Million (2023-2028)
  • Table 178. Europe Cancer Screening, by Application USD Million (2023-2028)
  • Table 179. Europe Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 180. Germany Cancer Screening, by Type USD Million (2023-2028)
  • Table 181. Germany Cancer Screening, by Application USD Million (2023-2028)
  • Table 182. Germany Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 183. France Cancer Screening, by Type USD Million (2023-2028)
  • Table 184. France Cancer Screening, by Application USD Million (2023-2028)
  • Table 185. France Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 186. Italy Cancer Screening, by Type USD Million (2023-2028)
  • Table 187. Italy Cancer Screening, by Application USD Million (2023-2028)
  • Table 188. Italy Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 189. United Kingdom Cancer Screening, by Type USD Million (2023-2028)
  • Table 190. United Kingdom Cancer Screening, by Application USD Million (2023-2028)
  • Table 191. United Kingdom Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 192. Netherlands Cancer Screening, by Type USD Million (2023-2028)
  • Table 193. Netherlands Cancer Screening, by Application USD Million (2023-2028)
  • Table 194. Netherlands Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 195. Rest of Europe Cancer Screening, by Type USD Million (2023-2028)
  • Table 196. Rest of Europe Cancer Screening, by Application USD Million (2023-2028)
  • Table 197. Rest of Europe Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 198. MEA Cancer Screening, by Country USD Million (2023-2028)
  • Table 199. MEA Cancer Screening, by Type USD Million (2023-2028)
  • Table 200. MEA Cancer Screening, by Application USD Million (2023-2028)
  • Table 201. MEA Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 202. Middle East Cancer Screening, by Type USD Million (2023-2028)
  • Table 203. Middle East Cancer Screening, by Application USD Million (2023-2028)
  • Table 204. Middle East Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 205. Africa Cancer Screening, by Type USD Million (2023-2028)
  • Table 206. Africa Cancer Screening, by Application USD Million (2023-2028)
  • Table 207. Africa Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 208. North America Cancer Screening, by Country USD Million (2023-2028)
  • Table 209. North America Cancer Screening, by Type USD Million (2023-2028)
  • Table 210. North America Cancer Screening, by Application USD Million (2023-2028)
  • Table 211. North America Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 212. United States Cancer Screening, by Type USD Million (2023-2028)
  • Table 213. United States Cancer Screening, by Application USD Million (2023-2028)
  • Table 214. United States Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 215. Canada Cancer Screening, by Type USD Million (2023-2028)
  • Table 216. Canada Cancer Screening, by Application USD Million (2023-2028)
  • Table 217. Canada Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 218. Mexico Cancer Screening, by Type USD Million (2023-2028)
  • Table 219. Mexico Cancer Screening, by Application USD Million (2023-2028)
  • Table 220. Mexico Cancer Screening, by Diseases USD Million (2023-2028)
  • Table 221. Cancer Screening: by Type(USD/Units)
  • Table 222. Research Programs/Design for This Report
  • Table 223. Key Data Information from Secondary Sources
  • Table 224. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Screening: by Type USD Million (2017-2022)
  • Figure 5. Global Cancer Screening: by Application USD Million (2017-2022)
  • Figure 6. Global Cancer Screening: by Diseases USD Million (2017-2022)
  • Figure 7. South America Cancer Screening Share (%), by Country
  • Figure 8. Asia Pacific Cancer Screening Share (%), by Country
  • Figure 9. Europe Cancer Screening Share (%), by Country
  • Figure 10. MEA Cancer Screening Share (%), by Country
  • Figure 11. North America Cancer Screening Share (%), by Country
  • Figure 12. Global Cancer Screening: by Type USD/Units (2017-2022)
  • Figure 13. Global Cancer Screening share by Players 2022 (%)
  • Figure 14. Global Cancer Screening share by Players (Top 3) 2022(%)
  • Figure 15. Global Cancer Screening share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott (United States) Revenue: by Geography 2022
  • Figure 19. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Roche (Switzerland) Revenue: by Geography 2022
  • Figure 21. Fujirebio Diagnostics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Fujirebio Diagnostics, Inc. (United States) Revenue: by Geography 2022
  • Figure 23. BioMérieux (France) Revenue, Net Income and Gross profit
  • Figure 24. BioMérieux (France) Revenue: by Geography 2022
  • Figure 25. Beckman Coulter (United States) Revenue, Net Income and Gross profit
  • Figure 26. Beckman Coulter (United States) Revenue: by Geography 2022
  • Figure 27. Clarient (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Clarient (Switzerland) Revenue: by Geography 2022
  • Figure 29. Siemens (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Siemens (Germany) Revenue: by Geography 2022
  • Figure 31. DiaSorin (Italy) Revenue, Net Income and Gross profit
  • Figure 32. DiaSorin (Italy) Revenue: by Geography 2022
  • Figure 33. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Qiagen (Germany) Revenue: by Geography 2022
  • Figure 35. Global Cancer Screening: by Type USD Million (2023-2028)
  • Figure 36. Global Cancer Screening: by Application USD Million (2023-2028)
  • Figure 37. Global Cancer Screening: by Diseases USD Million (2023-2028)
  • Figure 38. South America Cancer Screening Share (%), by Country
  • Figure 39. Asia Pacific Cancer Screening Share (%), by Country
  • Figure 40. Europe Cancer Screening Share (%), by Country
  • Figure 41. MEA Cancer Screening Share (%), by Country
  • Figure 42. North America Cancer Screening Share (%), by Country
  • Figure 43. Global Cancer Screening: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Roche (Switzerland)
  • Fujirebio Diagnostics, Inc. (United States)
  • BioMérieux (France)
  • Beckman Coulter (United States)
  • Clarient (Switzerland)
  • Siemens (Germany)
  • DiaSorin (Italy)
  • Qiagen (Germany)
Additional players considered in the study are as follows:
Xeptagen (Spain) , Orion Genomics. (United States) , Hologic, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 214 Pages 97 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Screening Market Quantitative research analysis
Global Cancer Screening Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cancer Screening market are Abbott (United States), Roche (Switzerland), Fujirebio Diagnostics, Inc. (United States), BioMérieux (France), Beckman Coulter (United States), Clarient (Switzerland), Siemens (Germany), DiaSorin (Italy) and Qiagen (Germany), to name a few.
North America is dominating the Cancer Screening Market.
"Fluctuation of Data and Accuracy of the Equipment is anticipated to challenge the market" is seen as one of the major challenges by many Industry Players of Cancer Screening Market
The Cancer Screening market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Cancer Screening market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Cancer Screening Market Report?

Have a Query? Click Here

Other Related Reports

Bio-Implants Comprehensive Study by Type (Cardiovascular Implants, Spinal implants, Orthopedic Implants, Dental Implants, Ophthalmic Implants, Others), End Users (Hospitals, Clinics, Ambulatory Surgi...
$ 3800
Nasogastric Tube Comprehensive Study by Type (Levin Tube, Sengstaken-Blakemore Tube, Others), Application (Hospitals, Clinics, Others), Distribution Channel (Online, Offline), End-User (Children Use,...
$ 3500
Surgical Drains Comprehensive Study by Type (Active, Passive), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Online, Offline), End-Use (Orthopedic, CVD,...
$ 3450
Ambulatory Blood Pressure Monitors Comprehensive Study by Type (Arm Device, Wrist Device), Application (Clinic, Hospital, Ambulatory Surgical Centers, Home), Components (Carrying Case, Cuff, Monitor)...
$ 3350
Invasive Brain Monitoring Device Comprehensive Study by Type (Electroencephalography (EEG) Devices, Magnetoencephalography (MEG) Devices, Transcranial Doppler (TCD) Devices, Intracranial Pressure (IC...
$ 3750
Portable Ecg Monitor Comprehensive Study by Type (NIBP Monitors, IBP Monitors, EKG Monitors), Equipment (ECG Monitoring Equipment, Holter Monitoring Systems, ECG Stress Testing Systems, Event Monitor...
$ 3800